301: Biotech Mega-rounds, A Cancer Vaccine Setback & CEOs Keep Their Promise The Readout Loud podcast

Artwork

Indhold leveret af STAT. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af STAT eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

The Readout Loud « »
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

7M ago 31:37

Del

MP3•Episode hjem

Indhold leveret af STAT. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af STAT eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.

Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

… continue reading

331 episoder

#Business #Stats

Artwork

301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

The Readout Loud

published 7M ago

Del

MP3•Episode hjem

Indhold leveret af STAT. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af STAT eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.

Here’s where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.

… continue reading

331 episoder

#Business #Stats

Tutti gli episodi

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner